trending Market Intelligence /marketintelligence/en/news-insights/trending/PxO5MrHZNxJ7IFHQhIwD6g2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Allergan's Botox gets another US FDA nod for muscle disorder in children

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Allergan's Botox gets another US FDA nod for muscle disorder in children

The U.S. Food and Drug Administration approved an expanded use of Allergan PLC's blockbuster drug Botox to treat children with lower limb spasticity, a type of muscle disorder.

Spasticity is a neurological condition that causes the muscles to continuously contract, leading to muscle stiffness and tightness in the upper and lower limbs that can interfere with movement.

The Irish pharmaceutical giant said the approval includes patients two to 17 years of age with lower limb spasticity but excludes lower limb spasticity caused by cerebral palsy — a type of muscle disorder that is caused by damage to an immature brain as it develops. The exclusion is due to marketing exclusivity by another company.

The FDA approval was backed by data from a phase 3 study, which included more than 300 patients aged two to 17 years old with lower limb spasticity. Some patients also had cerebral palsy, the company said.

Botox was approved by the FDA in June to treat children with upper limb spasticity. Allergan had submitted two supplemental biologics license applications to the U.S. regulator in March seeking approval for the drug in these indications.

Botox, Allergan's top-selling product, is approved in the U.S. for both upper and lower limb spasticity in adults 18 years old and above.

The drug is more commonly known as a cosmetic product, generating $3.58 billion in sales for Allergan in 2018. The company is being acquired by AbbVie Inc. in an $84.2 billion deal.